Prognostic vlaue of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation

Leukemia and Lymphoma

Volumn 46, Issue 6, 2005, Pages 861-867

  Jabbour, E ^a   Peslin, N ^a   Arnaud, P ^a   Ferme, C ^a   Carde, P ^a   Vantelon, J M ^a   Bocaccio, C ^a   Bourhis, J H ^a   Koscielny, S ^a   Ribrag, V ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

BEAM; High dose therapy; IPI lymphoma; Lymphoma; Prognostic factor; Salvage chemotherapy

Indexed keywords

AMSACRINE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MITOGUAZONE; PREDNISONE; STEROID; VINCRISTINE; ANTINEOPLASTIC AGENT; BEAM REGIMEN; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ADULT; AGE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; ADOLESCENT; AGED; AUTOTRANSPLANTATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; ONCOLOGY; RECURRENT DISEASE; REMISSION; STANDARD; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MEDICAL ONCOLOGY; MELPHALAN; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 21844442578     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500054350     Document Type: Article

References (18)

1. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med1993;328:1002-1006.
2. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH-87 protocol. A Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030.
3. Tilly H, Mounier N, Lederlin P et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH 87-1 study. J Clin Oncol 2000;18:1309-1315.
4. Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-1349.
5. Philip T, Guglielmi C, Haagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
6. Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96:2399-2404.
7. Vose JM. High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma. Ann Oncol 1998;9 (Suppl. 1):S1-S3.
8. Shipp MA, Abeloff MD, Antman KH et al. International Consensus Conference on High-dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999;17:423-429.
9. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-1996.
10. Blay J, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562-3568.
11. The International Non-Hodgkin's Lymphoma Prognostic Factor Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
12. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-1498.
13. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406-413.
14. Stiff PJ, Dahlberg S, Forman SJ. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - A Southwest Oncology Group Trial. J Clin Oncol 1998;16:48-55.
15. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1846-1851.
16. De Kreuk M, Ossenkoppele GJ, Meijer CJ et al. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1996;17:963-971.
17. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993;11:2351-2361.
18. Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1991;6:3264-3269.